The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.

The discovery of NO, CO, and H2S as gasotransmitters and their beneficial role in multiple physiological functions opened an era of research devoted to exogenously deliver them as therapeutic agents. However, the gaseous nature of these molecules demands new forms of administration that enable to control the location, dosage and timing of their delivery. Porous materials are among the most suitable scaffolds to store, deliver and release gasotranmistters due to their high surface area, tunable composition and reactivity. This review highlights the strategies employed to load and release gasotransmitters from different kinds of porous materials, including zeolites, mesoporous silica, metal-organic frameworks and protein assemblies.

Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine. Graphical abstract

No abstract

No abstract

No abstract

Bacteriophages are responsible for significant material and time losses in the dairy industry. This because these viruses infect the selected lactic starter cultures used for milk fermentation, i.e., the first stage toward cheese production. Standard detection techniques are time- and labor-consuming, causing huge costs related to production plant sanitation and product wasting. A new type of biosensor for early detection of bacteriophage contamination is highly demanded by the milk processing market, and inkjet-printed electrochemical sensors could be the answer. Inkjet printing is a well-known technology that has been revisited in recent years, using silver nanoparticle (AgNP) based inks for low-cost and easy fabrication of sensing and biosensing systems on flexible and eco-compatible substrates. In this research, we studied inkjet printing for the manufacturing of both interdigitated electrodes arrays (IDEAs), and a versatile system to monitor bacterial cultures by electrochemical impedance spectroscopy (EIS). In particular, we studied this biosensing system for the detection of bacteriophages by comparing its performance with standard microbiological methods. We performed electrical and morphological characterizations of the devices produced with a consumer-use inkjet printer with commercial AgNPs ink on flexible substrates, such as office paper, polyethylene (PET), and photo paper. We used light microscopy optical analysis, profilometry, atomic force microscopy (AFM), and scanning electron microscopy (SEM) imaging to define the objects resolution, their real dimensions, and thickness. We also investigated the devices’ conductivity and layout, by EIS measurements with a standard buffer solution, i.e., phosphate buffered saline (PBS). Finally, we tested our system by monitoring Lactococcus lactis cultures and bacteriophage infection. We compared the results to those obtained by two standard microbiological methods in terms of response time, proving that our technique requires less than half the time of other methods and no specialized personnel.

Graphene-based materials are of interest in electrochemical biosensing due to their unique properties, such as high surface areas, unique electrochemical properties, and biocompatibility. However, the scalable production of graphene electrodes remains a challenge; it is typically slow, expensive, and inefficient. Herein, we reported a simple, fast, and maskless method for large-scale, low-cost reduced graphene oxide electrode fabrication; using direct writing (laser scribing and inkjet printing) coupled with a stamp-transferring method. In this process, graphene oxide is simultaneously reduced and patterned with a laser, before being press-stamped onto polyester sheets. The transferred electrodes were characterized by SEM, XPS, Raman, and electrochemical methods. The biosensing utility of the electrodes was demonstrated by developing an electrochemical test for Escherichia coli. These biosensors exhibited a wide dynamic range (917–2.1 × 107 CFU/mL) of low limits of detection (283 CFU/mL) using just 5 μL of sample. The test was also verified in spiked artificial urine, and the sensor was integrated into a portable wireless system driven and measured by a smartphone. This work demonstrates the potential to use these biosensors for real-world, point-of-care applications. Hypothetically, the devices are suitable for the detection of other pathogenic bacteria.